Kinnate Biopharma Inc.
KNTE
Price:
$2.65
Market Cap:
$124.99M
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinna...[Read more]
Industry
Biotechnology
IPO Date
2020-12-03
Stock Exchange
NASDAQ
Ticker
KNTE
The ROE as of August 2024 (TTM) for Kinnate Biopharma Inc. (KNTE) is -59.00%
According to Kinnate Biopharma Inc.’s latest financial reports and current stock price. The company's current ROE is -59.00%. This represents a change of 302.03% compared to the average of -14.68% of the last 4 quarters.
Kinnate Biopharma Inc. (KNTE) Historical ROE (quarterly & annually)
How has KNTE ROE performed in the past?
The mean historical ROE of Kinnate Biopharma Inc. over the last ten years is -31.80%. The current -59.00% ROE has changed 85.55% with respect to the historical average. Over the past ten years (40 quarters), KNTE's ROE was at its highest in in the December 2019 quarter at 22.54%. The ROE was at its lowest in in the September 2023 quarter at -17.82%.
Average
-31.80%
Median
-39.51%
Minimum
-100.26%
Maximum
68.20%
Kinnate Biopharma Inc. (KNTE) ROE by Quarter and Year
Discovering the peaks and valleys of Kinnate Biopharma Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 210.63%
Maximum Annual ROE = 68.20%
Minimum Annual Increase = -168.02%
Minimum Annual ROE = -100.26%
| Year | ROE | Change |
|---|---|---|
| 2023 | -70.70% | 38.57% |
| 2022 | -51.02% | 82.31% |
| 2021 | -27.99% | 210.63% |
| 2020 | -9.01% | -113.21% |
| 2019 | 68.20% | -168.02% |
Kinnate Biopharma Inc. (KNTE) Average ROE
How has KNTE ROE performed in the past?
The current ROE of Kinnate Biopharma Inc. (KNTE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-49.90%
5-year avg
-18.10%
10-year avg
-31.80%
Kinnate Biopharma Inc. (KNTE) ROE vs. Peers
How is KNTE’s ROE compared to its peers?
Kinnate Biopharma Inc.’s ROE is greater than Ambrx Biopharma Inc. (-34.98%), greater than Acelyrin, Inc. (-81.29%), greater than Windtree Therapeutics, Inc. (-123.93%), greater than Palisade Bio, Inc. (-124.86%), greater than Century Therapeutics, Inc. (-65.37%), greater than Passage Bio, Inc. (-70.73%), greater than Homology Medicines, Inc. (-100.91%), greater than Generation Bio Co. (-92.86%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Erasca, Inc. (-131.94%), greater than Kronos Bio, Inc. (-68.82%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Surrozen, Inc. (-178.66%), greater than Bolt Biotherapeutics, Inc. (-61.40%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Kezar Life Sciences, Inc. (-54.50%),
| Company | ROE | Market cap |
|---|---|---|
| -34.98% | $1.77B | |
| -81.29% | $423.19M | |
| -123.93% | $1.66M | |
| -124.86% | $4.25M | |
| -65.37% | $123.69M | |
| -70.73% | $43.48M | |
| -100.91% | $3.02M | |
| -92.86% | $145.50M | |
| -57.89% | $773.92M | |
| -37.20% | $989.87M | |
| -24.51% | $181.50M | |
| -70.40% | $349.21M | |
| -18.48% | $264.42M | |
| -131.94% | $807.96M | |
| -68.82% | $59.36M | |
| -44.60% | $374.42M | |
| -28.01% | $1.64B | |
| -178.66% | $29.60M | |
| -61.40% | $24.78M | |
| -37.84% | $513.64M | |
| -44.73% | $1.97B | |
| -54.50% | $40.82M |
Build a custom stock screener for Kinnate Biopharma Inc. (KNTE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kinnate Biopharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Kinnate Biopharma Inc. (KNTE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Kinnate Biopharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Kinnate Biopharma Inc.'s ROE?
How is the ROE calculated for Kinnate Biopharma Inc. (KNTE)?
What is the highest ROE for Kinnate Biopharma Inc. (KNTE)?
What is the 3-year average ROE for Kinnate Biopharma Inc. (KNTE)?
What is the 5-year average ROE for Kinnate Biopharma Inc. (KNTE)?
How does the current ROE for Kinnate Biopharma Inc. (KNTE) compare to its historical average?